ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.
A number of other equities research analysts also recently commented on ANIP. Canaccord Genuity reiterated a “buy” rating and set a $66.00 price target (up from $60.00) on shares of ANI Pharmaceuticals in a report on Monday, October 16th. Zacks Investment Research downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. ValuEngine downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th. Finally, TheStreet upgraded shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, November 16th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $71.00.
Shares of ANI Pharmaceuticals (NASDAQ ANIP) opened at $70.90 on Wednesday. The company has a market cap of $833.18, a PE ratio of 112.54 and a beta of 2.90. ANI Pharmaceuticals has a twelve month low of $42.23 and a twelve month high of $74.70. The company has a current ratio of 3.45, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. The business had revenue of $48.16 million during the quarter, compared to the consensus estimate of $48.12 million. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The company’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.09 earnings per share. research analysts predict that ANI Pharmaceuticals will post 3.59 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of ANIP. Schwab Charles Investment Management Inc. grew its holdings in ANI Pharmaceuticals by 38.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 64,661 shares of the specialty pharmaceutical company’s stock valued at $4,168,000 after purchasing an additional 17,920 shares during the period. Bank of Montreal Can grew its holdings in ANI Pharmaceuticals by 681.8% in the fourth quarter. Bank of Montreal Can now owns 2,408 shares of the specialty pharmaceutical company’s stock valued at $156,000 after purchasing an additional 2,100 shares during the period. Louisiana State Employees Retirement System purchased a new stake in ANI Pharmaceuticals in the fourth quarter valued at approximately $251,000. Thomson Horstmann & Bryant Inc. grew its holdings in ANI Pharmaceuticals by 33.2% in the fourth quarter. Thomson Horstmann & Bryant Inc. now owns 20,101 shares of the specialty pharmaceutical company’s stock valued at $1,295,000 after purchasing an additional 5,006 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in ANI Pharmaceuticals in the third quarter valued at approximately $530,000. Institutional investors and hedge funds own 55.08% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/24/ani-pharmaceuticals-anip-downgraded-by-bidaskclub-to-hold.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.